Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2025, totaled approximately $408.2 million VYGLXIA NDA for spinocerebellar ataxia ...

Now, it’s worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for ...

Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON (R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This ...

Q2 2025 Earnings Call Transcript August 6, 2025 Travere Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.

Management expects continued revenue growth driven by robust FILSPARI demand in IgA nephropathy and potential additional milestone payments. Cline said, "we expect continued revenue growth driven by ...

As global markets grapple with renewed trade tensions and economic uncertainties, Asian equities present a mixed landscape, with some indices experiencing declines amid these challenges. In this ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ: TVTX) reported stronger-than-expected second quarter 2025 financial results on Wednesday, driven by significant growth in FILSPARI sales, sending ...

Purespring Therapeutics has received approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002, to treat IgA nephropathy (IgAN). Approval from the UK ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shanghai, China –August 6, 2025 – Everest Medicines (HKEX 1952,“Everest”, or the Company), a biopharmaceutical company focused on the discovery, cl ...

Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R)'is ...